| Статус: | Completed |
| Фаза: | Phase 1 |
| Начало: | 21 сентября 2018 г. |
| Окончание: | 8 октября 2018 г. |
| Описание: | This was an open-label, randomized, single-center, single-dose, two-treatment, two-sequence, two-period, crossover, comparative study, where each subject was randomly assigned to the reference or the test formulation in each period of the study (sequences RT or TR), in order to evaluate if both formulations are bioequivalent.The study was conducted in multiple groups. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | Phase 1 |
| Начало: | 28 июля 2018 г. |
| Окончание: | 13 августа 2018 г. |
| Описание: | This is an open-label, randomized, single-center, single-dose, two-treatment, two-sequence, two-period, crossover, comparative study, where each subject will be randomly assigned to the reference or the test formulation in each period of the study (sequences RT or TR), in order to evaluate if both formulations are bioequivalent. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | Phase 1 |
| Начало: | 11 июня 2018 г. |
| Окончание: | 25 июня 2018 г. |
| Описание: | To demonstrate bioequivalence of single dose test formulation of Ibuprofen,oral suspension 200 mg/5 ml (containing ibuprofen 200 mg) of Pharmtechnology LLC, Republic of Belarus with reference Nurofen® for Children, oral suspension 100 mg / 5 ml (containing ibuprofen 100 mg) of "Reckitt Benckiser Healthcare International Ltd, .", UK in normal, healthy, adult, human subjects under fasting conditions.To monitor adverse events and ensure the safety |
| смотреть на ClinicalTrials.gov |